Healthcare Industry News: Acute Coronary Syndrome
News Release - October 25, 2007
Minnesota Based Lumen Biomedical Goes Global with Innovative Products for Patients with Vascular DiseasePLYMOUTH, Minn.--(HSMN NewsFeed)--Lumen Biomedical, Inc. gained access to the international market by receiving foreign certification (CE Mark) of their FiberNet® Embolic Protection System (EPS) and Xtract™ Aspiration Catheter. Intended for patients with vascular disease, the FiberNet EPS is a 3-dimensional matrix of fibers designed to capture particles released from stent placement in a narrowed carotid artery.
Carotid artery disease is a major cause of ischemic stroke afflicting over 850,000 people in Europe causing over 200,000 deaths annually. The minimally-invasive Carotid Artery Stenting (CAS) procedure has evolved over the years requiring embolic protection to be used in every patient. The FiberNet EPS captures particles released with a highly-effective filter made of hundreds of fibers to prevent microscopic debris from traveling to the brain. After the particles have been captured, the FiberNet filter is then retracted into its own retrieval catheter under aspiration and removed from the patient.
With over 500,000 patients suffering annually from Acute Coronary Syndrome (ACS), tools are being made to remove these harmful blood clots from arterial vessels. Lumen Biomedical’s second product line is their Xtract Aspiration Catheter cleared for removal of fresh, soft emboli or thrombi from arteries. This novel tool has powerful suction capabilities attributed to a large circular aspiration lumen. Clots can create severe complications in patients by restricting or interrupting blood flow within a vessel. It is therefore critical for physicians to be able to easily remove these emboli from the body. The Xtract Catheter is designed to effectively maneuver through a patient’s vasculature with a braided, flexible shaft and a soft curved tip. Once the catheter is placed adjacent to the clot, continuous and directional suction ensures quick retrieval. The Xtract Aspiration Catheter is now available in three sizes (4.2, 5 and 5.8 French) making it the largest catheter of this type to penetrate the market.
“Lumen Biomedical is excited to expand our efforts internationally,” remarks Randy LaBounty, Vice President of Clinical and Regulatory Affairs. “We are fortunate to have received such positive feedback from our physicians ensuring our product family is truly the next generation in the vascular field.”
About Lumen Biomedical, Inc.:
Lumen Biomedical is driven towards the development and commercialization of unique interventional devices that can be used in any anatomical area where embolic protection or thrombus removal may be required. These markets include peripheral vascular and coronary applications with potentials approaching 1.6 billion worldwide. To learn more about Lumen Biomedical, Inc. visit the web site at www.lumenbio.com.
Source: Lumen Biomedical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.